AstraZeneca discontinues Phase 3 trial of Truqap in metastatic castration-resistant prostate cancer Ruchika Sharma30 April 2025 12:14 PM ISTTruqap was discovered by AstraZeneca subsequent to a collaboration with Astex Therapeutics.
AstraZeneca Truqap, Faslodex combo approved in EU for advanced ER-positive breast cancer Ruchika Sharma21 Jun 2024 10:00 AM ISTCambridge: AstraZeneca has announced that Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the...
AstraZeneca Truqap plus Faslodex recommended for approval in EU by CHMP for advanced ER-positive breast cancer Ruchika Sharma1 May 2024 11:30 AM ISTCambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been recommended for approval in the...
AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer Ruchika Sharma31 March 2024 2:30 PM ISTCambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult...
Truqap plus Faslodex approved in US for advanced HR-positive breast cancer: AstraZeneca Ruchika Sharma18 Nov 2023 2:14 PM ISTCambridge: AstraZeneca’s Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in the US for the treatment of adult...
AstraZeneca breast cancer drug combination gets USFDA okay Ruchika Sharma17 Nov 2023 11:37 AM ISTTruqap belongs to a class of drugs known as AKT inhibitors and works by targeting the AKT1 gene mutation, which is responsible for growth and...
